Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

doi:10.1182/blood-2006-02-005702

Article

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

Blood - 1 Dec 2006

DeAngelo Daniel J, Stone Richard M, Heaney Mark L, Nimer Stephen D, Paquette Ronald L, Klisovic Rebecca B, Caligiuri Michael A, Cooper Michael R, Lecerf Jean-Michel, Karol Michael D, Sheng Shihong, Holford Nick, Curtin Peter T, Druker Brian J, Heinrich Michael C

Abstract excerpt

Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT. Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor p...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

Abstract excerpt

Topics

Related research